International Journal of High Risk Behaviors and Addiction

Published by: Kowsar

Inpatient Buprenorphine-Assisted Withdrawal for Treatment of Vulnerable Adolescents with Opioids Use Disorder in Zahedan, Iran: An Observational Study

Mahboubeh Firouzkouhi Moghadam 1 , 2 , Seyed Sepehr Hashemian 3 , Ahmad Hajebi 4 , Masoud Pishjoo 5 and Alireza Noroozi 6 , 7 , *
Authors Information
1 Child and Adolescent Psychiatry Department, Zahedan University of Medical Sciences, Zahedan, IR Iran
2 Research Center for Children and Adolescents Health, Zahedan University of Medical Sciences, Zahedan, IR Iran
3 Department of Psychology and Educational Sciences, Allameh Tabataba'i University, Tehran, IR Iran
4 Psychiatric Department, Research Center for Addiction and Risky Behavior (ReCARB), Iran University of Medical Sciences (IUMS), Tehran, IR Iran
5 Department of Neurosurgery, Mashhad University of Medical Sciences, Mashhad, IR Iran
6 Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, IR Iran
7 Department of Neuroscience and Addiction Studeis, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, IR Iran
Article information
  • International Journal of High Risk Behaviors and Addiction: March 31, 2019, 8 (1); e66470
  • Published Online: December 3, 2018
  • Article Type: Research Article
  • Received: January 19, 2018
  • Revised: September 10, 2018
  • Accepted: October 25, 2018
  • DOI: 10.5812/ijhrba.66470

To Cite: Firouzkouhi Moghadam M, Hashemian S S, Hajebi A, Pishjoo M, Noroozi A. Inpatient Buprenorphine-Assisted Withdrawal for Treatment of Vulnerable Adolescents with Opioids Use Disorder in Zahedan, Iran: An Observational Study, Int J High Risk Behav Addict. 2019 ; 8(1):e66470. doi: 10.5812/ijhrba.66470.

Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Amin-Esmaeili M, Rahimi-Movaghar A, Sharifi V, Hajebi A, Radgoodarzi R, Mojtabai R, et al. Epidemiology of illicit drug use disorders in Iran: Prevalence, correlates, comorbidity and service utilization results from the Iranian mental health survey. Addiction. 2016;111(10):1836-47. doi: 10.1111/add.13453. [PubMed: 27177849].
  • 2. Iran Drug Control Headquarter. Iran Drug Control Headquarter year book of 1394 [2015]. Main results of national epidemiologic study of drug use in Iran, 2011 (bureau of planning and information technologies). Tehran: Drug Control Headquarter Publications; 2015.
  • 3. Akhgari M, Jokar F, Bahmanabadi L, Etemadi Aleagha A. Street-level heroin seizures in Iran: A survey of components. J Subst Use. 2012;17(4):348-55. doi: 10.3109/14659891.2011.592898.
  • 4. Mohammadkhani S. [Prevalence of cigarette, alcohol and psychoactive substances use among Iranian adolescents]. J Kerman Uni. 2011;19(1):32-48. Persian.
  • 5. Ahmad Khaniha AR, Torknejad S, Hosseini-Moghadam MH. [Epidemiology of depression and sexual abuse among street children]. Andisheh va Raftar. 2002;8(1):14-20. Persian.
  • 6. Ahmad Khaniha AR, Hakim Shooshtari M, Mohammadian M, Bidaki R, Pourrashidi Boshrabadi A. Familial characteristics of street children in Tehran, Iran. Iran J Psychiatry Behav Sci. 2014;8(2):86-9. [PubMed: 25053962]. [PubMed Central: PMC4105609].
  • 7. Ataei B, Nokhodian Z, Babak A, Shaaei P, Mohammadzadeh M, Sadeghi M. [Prevalence of hepatitis C and HIV among street children and adolescents in Isfahan]. J Med School. 2009;67(11):811-6. Persian.
  • 8. Vameghi M, Sajjadi H, Rafiei H, Rashidian A. [Systematic review of street children studies during last decade (poverty, risk factor for turning to street children)]. Soc Welfare Q. 1388;9(35):337-78. Persian.
  • 9. Vameghi M, Dejman M, Rafiei H, Forouzan A, Roshanfekr P. [Rapid situational assessment of street children in Tehran]. Soc Stud Res Iran. 1394;4(1):33-57. Persian.
  • 10. Ministry of Welfare and Social Security. [Regulation for regularization of street children]. 2005. Available from:
  • 11. Deas D, Thomas SE. An overview of controlled studies of adolescent substance abuse treatment. Am J Addict. 2001;10(2):178-89. [PubMed: 11444159].
  • 12. Galanter M, Glickman L, Singer D. An overview of outpatient treatment of adolescent substance abuse. Subst Abus. 2007;28(2):51-8. doi: 10.1300/J465v28n02_07. [PubMed: 19266713].
  • 13. Kaminer Y, Marsch LA. Pharmacotherapy of adolescent substance use disorders. In: Kaminer Y, Winters KC, editors. Clinical manual of adolescent substance abuse treatment. Arlington, VA, USA: American Psychiatric Publishing; 2011.
  • 14. Marsch LA, Bickel WK, Badger GJ, Stothart ME, Quesnel KJ, Stanger C, et al. Comparison of pharmacological treatments for opioid-dependent adolescents: A randomized controlled trial. Arch Gen Psychiatry. 2005;62(10):1157-64. doi: 10.1001/archpsyc.62.10.1157. [PubMed: 16203961].
  • 15. Marsch LA, Moore SK, Borodovsky JT, Solhkhah R, Badger GJ, Semino S, et al. A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults. Addiction. 2016;111(8):1406-15. doi: 10.1111/add.13363. [PubMed: 26918564]. [PubMed Central: PMC4940230].
  • 16. Woody GE, Poole SA, Subramaniam G, Dugosh K, Bogenschutz M, Abbott P, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: A randomized trial. JAMA. 2008;300(17):2003-11. doi: 10.1001/jama.2008.574. [PubMed: 18984887]. [PubMed Central: PMC2610690].
  • 17. Lehmann WX. The use of 1-alpha-acetyl-methadol (LAAM) as compared to methadone in the maintenance and detoxification of young heroin addicts. 1973 [proceedings]. NIDA Res Monogr. 1976;(8):82-3. [PubMed: 792705].
  • 18. Bell J, Mutch C. Treatment retention in adolescent patients treated with methadone or buprenorphine for opioid dependence: A file review. Drug Alcohol Rev. 2006;25(2):167-71. doi: 10.1080/09595230500537670. [PubMed: 16627307].
  • 19. Smyth BP, Fagan J, Kernan K. Outcome of heroin-dependent adolescents presenting for opiate substitution treatment. J Subst Abuse Treat. 2012;42(1):35-44. doi: 10.1016/j.jsat.2011.07.007. [PubMed: 21940134].
  • 20. Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Lintzeris N. Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database Syst Rev. 2016;(5). CD011117. doi: 10.1002/14651858.CD011117.pub2. [PubMed: 27157143].
  • 21. Momtazi S, Noroozi A, Rawson R. An overview of Iran drug treatment and harm reduction programs. In: el-Guebaly N, Carrà G, Galanter M, editors. Textbook of addiction treatment international perspectives. Springer; 2015. p. 543-54. doi: 10.1007/978-88-470-5322-9_25.
  • 22. Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: Extrapolating from the laboratory to the clinic. Drug Alcohol Depend. 2003;70(2 Suppl):S13-27. [PubMed: 12738347].
  • 23. Firouzkouhi Moghadam M, Hashemian SS, Pishjoo M, Ghasemi S, Hajebi A, Noroozi A. Inpatient opioid withdrawal management of street children and adolescents admitted to child and adolescent psychiatric ward: A preliminary case series. Iran J Pediatr. 2016;26(4). e5133. doi: 10.5812/ijp.5133. [PubMed: 27729958]. [PubMed Central: PMC5046230].
  • 24. Center for Substance Abuse Treatment (CSAT). Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction, Series 40. DHHS Publication No. (SMA) 04-3939. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2014.
  • 25. Tanner-Smith EE, Wilson SJ, Lipsey MW. The comparative effectiveness of outpatient treatment for adolescent substance abuse: A meta-analysis. J Subst Abuse Treat. 2013;44(2):145-58. doi: 10.1016/j.jsat.2012.05.006. [PubMed: 22763198]. [PubMed Central: PMC3477300].
  • 26. Mee-Lee D. The ASAM criteria: treatment criteria for addictive, substance-related, and co-occurring conditions. 3rd ed. American Society of Addiction Medicine; 2013.
  • 27. Embleton L, Atwoli L, Ayuku D, Braitstein P. The journey of addiction: Barriers to and facilitators of drug use cessation among street children and youths in Western Kenya. PLoS One. 2013;8(1). e53435. doi: 10.1371/journal.pone.0053435. [PubMed: 23326428]. [PubMed Central: PMC3541137].
  • 28. Hogue A, Henderson CE, Schmidt AT. Multidimensional predictors of treatment outcome in usual care for adolescent conduct problems and substance use. Adm Policy Ment Health. 2017;44(3):380-94. doi: 10.1007/s10488-016-0724-7. [PubMed: 26884380]. [PubMed Central: PMC4987263].
  • 29. Connolly JA, Joly LE. Outreach with street-involved youth: A quantitative and qualitative review of the literature. Clin Psychol Rev. 2012;32(6):524-34. doi: 10.1016/j.cpr.2012.05.006. [PubMed: 22728669].
  • 30. Chakrabarti A, Woody GE, Griffin ML, Subramaniam G, Weiss RD. Predictors of buprenorphine-naloxone dosing in a 12-week treatment trial for opioid-dependent youth: Secondary analyses from a NIDA clinical trials network study. Drug Alcohol Depend. 2010;107(2-3):253-6. doi: 10.1016/j.drugalcdep.2009.10.014. [PubMed: 19948382]. [PubMed Central: PMC2821971].
  • 31. Embleton L, Mwangi A, Vreeman R, Ayuku D, Braitstein P. The epidemiology of substance use among street children in resource-constrained settings: A systematic review and meta-analysis. Addiction. 2013;108(10):1722-33. doi: 10.1111/add.12252. [PubMed: 23844822]. [PubMed Central: PMC3776018].
  • 32. Nikfarjam A, Shokoohi M, Shahesmaeili A, Haghdoost AA, Baneshi MR, Haji-Maghsoudi S, et al. National population size estimation of illicit drug users through the network scale-up method in 2013 in Iran. Int J Drug Policy. 2016;31:147-52. doi: 10.1016/j.drugpo.2016.01.013. [PubMed: 26980349].
  • 33. Hops H, Ozechowski TJ, Waldron HB, Davis B, Turner CW, Brody JL, et al. Adolescent health-risk sexual behaviors: Effects of a drug abuse intervention. AIDS Behav. 2011;15(8):1664-76. doi: 10.1007/s10461-011-0019-7. [PubMed: 21833690]. [PubMed Central: PMC3215274].
  • 34. Kirby D. Antecedents of adolescent initiation of sex, contraceptive use, and pregnancy. Am J Health Behav. 2002;26(6):473-85. [PubMed: 12437022].
  • 35. Subramaniam GA, Warden D, Minhajuddin A, Fishman MJ, Stitzer ML, Adinoff B, et al. Predictors of abstinence: National Institute of Drug Abuse multisite buprenorphine/naloxone treatment trial in opioid-dependent youth. J Am Acad Child Adolesc Psychiatry. 2011;50(11):1120-8. doi: 10.1016/j.jaac.2011.07.010. [PubMed: 22024000]. [PubMed Central: PMC3786351].
  • 36. Matson SC, Hobson G, Abdel-Rasoul M, Bonny AE. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic. J Addict Med. 2014;8(3):176-82. doi: 10.1097/ADM.0000000000000035. [PubMed: 24695018].
  • 37. Vourakis C. Admission variables as predictors of completion in an adolescent residential drug treatment program. J Child Adolesc Psychiatr Nurs. 2005;18(4):161-70. doi: 10.1111/j.1744-6171.2005.00031.x. [PubMed: 16236098].
  • 38. Strang J, McCambridge J, Best D, Beswick T, Bearn J, Rees S, et al. Loss of tolerance and overdose mortality after inpatient opiate detoxification: Follow up study. BMJ. 2003;326(7396):959-60. doi: 10.1136/bmj.326.7396.959. [PubMed: 12727768]. [PubMed Central: PMC153851].
  • 39. Bird SM, Hutchinson SJ. Male drugs-related deaths in the fortnight after release from prison: Scotland, 1996-99. Addiction. 2003;98(2):185-90. [PubMed: 12534423].
  • 40. Leach D, Oliver P. Drug-related death following release from prison: A brief review of the literature with recommendations for practice. Curr Drug Abuse Rev. 2011;4(4):292-7. [PubMed: 21834754].
  • 41. Pecoraro A, Fishman M, Ma M, Piralishvili G, Woody GE. Pharmacologically assisted treatment of opioid-dependent youth. Paediatr Drugs. 2013;15(6):449-58. doi: 10.1007/s40272-013-0041-5. [PubMed: 23912754].
  • 42. Hulse GK, Tait RJ. A pilot study to assess the impact of naltrexone implant on accidental opiate overdose in ‘high-risk’ adolescent heroin users. Addict Biol. 2003;8(3):337-42. doi: 10.1080/13556210310001602257. [PubMed: 13129836].
  • 43. Fishman MJ, Winstanley EL, Curran E, Garrett S, Subramaniam G. Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: Preliminary case-series and feasibility. Addiction. 2010;105(9):1669-76. doi: 10.1111/j.1360-0443.2010.03015.x. [PubMed: 20626723].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments